3.9 Neuromuscular Reversal & Vasoactive Airway Support
Key Takeaways
- Sugammadex provides rapid encapsulation and reversal of aminosteroid neuromuscular blocking agents (Rocuronium > Vecuronium); a dose of 16 mg/kg allows immediate reversal after 1.2 mg/kg Rocuronium RSI in rescue situations.
- Neostigmine relies on acetylcholinesterase inhibition and must be co-administered with an anticholinergic (Glycopyrrolate or Atropine) to prevent life-threatening muscarinic bradycardia and bronchorrhea.
- Push-dose pressors (Phenylephrine 50-200 mcg or Epinephrine 5-20 mcg) treat acute peri-intubation hypotension resulting from loss of sympathetic tone and positive pressure ventilation.
- Hemodynamic optimization before intubation using volume loading and pressors prevents peri-intubation cardiac arrest ('HOP' kill spikes: Hypotension, Hypoxemia, pH/Acidosis).
3.9 Neuromuscular Reversal & Vasoactive Airway Support
Emergency Rapid Sequence Induction (RSI) induces profound physiological stress. Transport clinicians must manage neuromuscular blockade reversal during emergency airway failures and administer push-dose vasopressors to prevent post-intubation hemodynamic collapse.
1. Neuromuscular Blockade Reversal Agents
Reversal of non-depolarizing neuromuscular blocking agents (NMBAs) is indicated when a patient cannot be intubated or ventilated, or when extubation criteria are met following transport.
NEUROMUSCULAR REVERSAL MECHANISMS
Sugammadex Encapsulation: Neostigmine AChE Inhibition:
+-------------+ +-----------------------+
| Sugammadex | | Neostigmine Blocks |
| Ring | | Acetylcholinesterase |
| +-------+ | +-----------+-----------+
| | Rocur | | |
| +-------+ | [ Increased Synaptic ACh ]
+-------------+ |
(Inactivated Complex Excreted) [ Competes with NMBD at NMJ ]
+
[ MUST Add Glycopyrrolate ]
(Prevents Severe Muscarinic Effects)
A. Sugammadex (Bridion)
Sugammadex is a modified $\gamma$-cyclodextrin designed to selectively encapsulate aminosteroid NMBAs (Rocuronium and Vecuronium).
- Mechanism of Action: Forms a lipophilic core complex with free Rocuronium in plasma at a $1:1$ ratio, rapidly lowering free drug concentration and driving the NMBA away from the neuromuscular junction (NMJ) back into plasma.
- Dosing Tiers:
- $2 \text{ mg/kg}$ IV: Routine reversal of shallow blockade (reappearance of $T_2$ twitch on Train-of-Four [TOF]).
- $4 \text{ mg/kg}$ IV: Reversal of deep blockade ($1-2$ post-tetanic counts [PTC] with zero TOF twitches).
- $16 \text{ mg/kg}$ IV: Immediate emergency rescue reversal following high-dose Rocuronium ($1.2 \text{ mg/kg}$) RSI in a "Cannot Intubate, Cannot Ventilate" scenario. Reverses blockade within $3 \text{ minutes}$.
- Drug Interactions & Warnings:
- Binds to oral contraceptives, decreasing their efficacy (equivalent to missing 1 daily dose; patients must use barrier contraception for 7 days).
- Ineffective against Succinylcholine or benzylisoquinoliniums (Cisatracurium, Atracurium).
B. Neostigmine + Anticholinergic Co-Administration
Neostigmine is a traditional acetylcholinesterase (AChE) inhibitor.
- Mechanism of Action: Inhibits breakdown of acetylcholine (ACh) in the synaptic cleft, elevating ACh concentration to outcompete non-depolarizing NMBAs at nicotinic receptors.
- Dosing: Neostigmine $0.03 - 0.07 \text{ mg/kg}$ IV (maximum single dose $5 \text{ mg}$). Requires at least partial spontaneous recovery ($T_2$ visible on TOF); ineffective for immediate rescue from deep paralysis.
- Mandatory Anticholinergic Co-Administration: Acetylcholinesterase inhibition elevates ACh at both nicotinic and muscarinic receptors, causing severe bradycardia, AV block, bronchospasm, hyper-salivation, and bronchorrhea. Neostigmine must always be co-administered with an anticholinergic:
| Anticholinergic Partner | Standard Dosing Ratio | Onset Matching | Central Nervous System Effects |
|---|---|---|---|
| Glycopyrrolate | $0.2 \text{ mg}$ Glycopyrrolate per $1.0 \text{ mg}$ Neostigmine | Matches Neostigmine onset ($2-3 \text{ min}$) perfectly | Does not cross blood-brain barrier (no sedation/confusion) |
| Atropine | $0.4 \text{ mg}$ Atropine per $1.0 \text{ mg}$ Neostigmine | Faster onset than Neostigmine ($1 \text{ min}$) | Crosses blood-brain barrier (risk of central anticholinergic syndrome) |
2. Peri-Intubation Hemodynamic Optimization & Push-Dose Pressors
Induction and positive pressure ventilation frequently trigger severe hypotension. Peri-intubation cardiac arrest occurs in up to $2-4%$ of emergency intubations, driven primarily by profound post-induction hypotension.
PATHOPHYSIOLOGY OF POST-INTUBATION HYPOTENSION
Induction Agents (Propofol/Midazolam) ---> Vasodilation + Sympatholysis
|
Positive Pressure Ventilation ---> High Intra-thoracic Pressure
|
Decreased Venous Return (Preload) ---> DROPPED CARDIAC OUTPUT
|
[ SEVERE HYPOTENSION ]
Push-Dose Vasopressor Protocols
Push-dose pressors provide immediate temporizing vasopressor support during the peri-intubation window while continuous infusions are prepared.
PUSH-DOSE PRESSOR MIXING GUIDE
Phenylephrine (100 mcg/mL): Epinephrine (10 mcg/mL):
1. Take 1 mL Phenylephrine (10 mg/mL) 1. Take 1 mL Epi 1:10,000 (100 mcg/mL)
2. Inject into 100 mL NS bag 2. Draw up into syringe with 9 mL NS
3. Yields 100 mcg/mL 3. Yields 10 mcg/mL ("Dirty Epi")
4. Dose: 50-200 mcg (0.5-2 mL) 4. Dose: 5-20 mcg (0.5-2 mL)
A. Push-Dose Phenylephrine
- Pharmacology: Pure $\alpha_1$-adrenergic receptor agonist causing arterial vasoconstriction and increased Systemic Vascular Resistance (SVR).
- Mixing Protocol: Draw $1 \text{ mL}$ of Phenylephrine ($10 \text{ mg/mL} = 10,000 \text{ mcg}$) and inject into a $100 \text{ mL}$ bag of Normal Saline. Concentration $= 100 \text{ mcg/mL}$.
- Dosing: Administer $50 - 200 \text{ mcg}$ ($0.5 - 2.0 \text{ mL}$) IV/IO every $2-5 \text{ minutes}$.
- Onset & Duration: Onset $1 \text{ minute}$; duration $10-20 \text{ minutes}$.
- Best Clinical Indication: Pure vasodilatory hypotension with normal or elevated baseline heart rate (causes reflex bradycardia).
B. Push-Dose Epinephrine
- Pharmacology: Direct $\alpha_1$, $\beta_1$, and $\beta_2$-agonist providing potent vasoconstriction, inotropy, chronotropy, and bronchodilation.
- Mixing Protocol: Take $1 \text{ mL}$ of Epinephrine $1:10,000$ ($100 \text{ mcg/mL}$) in a syringe and add $9 \text{ mL}$ of Normal Saline. Concentration $= 10 \text{ mcg/mL}$.
- Dosing: Administer $5 - 20 \text{ mcg}$ ($0.5 - 2.0 \text{ mL}$) IV/IO every $2-5 \text{ minutes}$.
- Onset & Duration: Onset $1 \text{ minute}$; duration $5-10 \text{ minutes}$.
- Best Clinical Indication: Post-induction hypotension accompanied by bradycardia, profound myocardial depression, or septic/anaphylactic shock.
3. Resuscitation Prior to Intubation
To prevent the "HOP" kill spikes (Hypotension, Oxygenation deficit, PH/Acidosis) during RSI:
- Pre-Intubation Volume Loading: Administer $500 - 1,000 \text{ mL}$ crystalloid or blood products prior to induction in hypovolemic patients.
- Hemodynamically Neutral Induction: Utilize Ketamine ($1.5-2.0 \text{ mg/kg}$ IV) or Etomidate ($0.3 \text{ mg/kg}$ IV) rather than Propofol ($1.5-2.5 \text{ mg/kg}$) or Midazolam ($0.1-0.2 \text{ mg/kg}$), which cause severe venodilation and myocardial depression.
A critical care transport team performs RSI with 1.2 mg/kg Rocuronium on a severe trauma patient. Intubation attempts fail due to massive airway edema, and a supraglottic airway fails to provide ventilation. What is the definitive pharmacologic rescue agent and dose to immediately reverse Rocuronium in this 'Cannot Intubate, Cannot Ventilate' scenario?
When administering Neostigmine to reverse neuromuscular blockade, why is it mandatory to co-administer an anticholinergic agent such as Glycopyrrolate?
Following RSI and positive pressure ventilation initiation, a septic patient's blood pressure drops from 110/70 mmHg to 72/40 mmHg with a heart rate of 55 bpm. The transport clinician prepares push-dose Epinephrine (10 mcg/mL). What is the correct initial dosing range?